Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;28(1):124-5.
doi: 10.5021/ad.2016.28.1.124. Epub 2016 Jan 28.

Treatment for Refractory Pruritus Using Oral Aprepitant

Affiliations

Treatment for Refractory Pruritus Using Oral Aprepitant

Joon Won Huh et al. Ann Dermatol. 2016 Feb.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. (A) Multiple excoriated papules and linear excoriations on the trunk before treatment. (B) At the 6-week follow-up, the excoriated papules and linear excoriations appear to be significantly improved.

References

    1. Lotts T, Ständer S. Research in practice: substance P antagonism in chronic pruritus. J Dtsch Dermatol Ges. 2014;12:557–559. - PubMed
    1. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One. 2010;5:e10968. - PMC - PubMed
    1. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 2012;13:1020–1024. - PubMed
    1. Booken N, Heck M, Nicolay JP, Klemke CD, Goerdt S, Utikal J. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br J Dermatol. 2011;164:665–667. - PubMed
    1. Vincenzi B, Tonini G, Santini D. Aprepitant for erlotinib-induced pruritus. N Engl J Med. 2010;363:397–398. - PubMed

LinkOut - more resources